Insider Trading June 4, 2026 09:46 PM

Fermi Inc. Executive Unloads $1M in Shares Amid Ongoing Corporate Restructuring

Chief Nuclear Construction Officer Uzman Mesut executes sell-to-cover transactions as the company navigates financial headwinds and leadership changes.

By Caleb Monroe FRMI

Uzman Mesut, serving as the Chief Nuclear Construction Officer at Fermi Inc. (NASDAQ: FRMI), completed a series of stock transactions on June 3, 2026, resulting in the sale of $1,000,393 worth of company common stock. The transactions, categorized as 'sell-to-cover' sales, were executed by a broker to satisfy withholding tax obligations associated with the vesting and delivery of share awards. This activity occurs against a backdrop of significant stock price depreciation, with Fermi's shares trading at $6.18, a sharp decline from their 52-week high of $36.99. The company is currently navigating a period of financial strain and internal governance shifts, having reported a substantial net loss in the first quarter of 2026 while facing calls for board changes from former leadership.

Fermi Inc. Executive Unloads $1M in Shares Amid Ongoing Corporate Restructuring
FRMI

Key Points

  • Uzman Mesut, Chief Nuclear Construction Officer at Fermi Inc., sold $1,000,393 worth of stock on June 3, 2026, through sell-to-cover transactions to cover withholding taxes upon award vesting.
  • Fermi Inc. reported a net loss of $189 million for the first quarter of 2026, primarily due to non-cash charges from share-based compensation, while revenue fell short of forecasts.
  • Citizens has maintained a Market Outperform rating for Fermi with a $30.00 price target, despite ongoing internal dynamics including a former CEO advocating for a board change.

Uzman Mesut, who holds the position of Chief Nuclear Construction Officer at Fermi Inc. (NASDAQ: FRMI), executed a series of stock transactions on June 3, 2026, resulting in the disposition of $1,000,393 worth of company common stock. The shares were transacted at a weighted average price of $6.31, with individual sales occurring within a price range of $6.20 to $6.50. These transactions were identified as "sell-to-cover" sales, executed by a broker to cover withholding taxes upon award vesting and share delivery.

According to a filing with the Securities and Exchange Commission, Mr. Mesut directly disposed of 79,032 shares of Fermi Inc. common stock. Additionally, an indirect sale of 79,509 shares of common stock was reported, held by Mr. Mesut's spouse. Following these transactions, Mr. Mesut directly holds 670,968 shares of Fermi Inc. common stock. An additional 670,491 shares are held indirectly by his spouse. These holdings include 500,000 shares of restricted common stock subject to time-based vesting conditions.

The sale comes as Fermi's stock has declined 81% over the past year, currently trading at $6.18 compared to its 52-week high of $36.99. According to InvestingPro analysis, the stock appears undervalued with a Fair Value of $8.63, placing it among potential opportunities on the Most Undervalued list, though the company faces challenges with weak financial health.

In other recent news, Fermi America reported a net loss of $189 million for the first quarter of 2026. This loss was primarily due to non-cash charges associated with share-based compensation. The company's revenue also fell short of forecasts, highlighting financial challenges. Despite these setbacks, Fermi America expressed continued commitment to its strategic projects and future growth initiatives.

In a related development, Citizens has reiterated its Market Outperform rating for Fermi, maintaining a price target of $30.00. This rating follows a conference call led by Fermi's former CEO, who is advocating for a board change. The former CEO has disputed claims regarding his termination. These developments reflect ongoing dynamics within the company.

Fermi America LLC Follow Analyze FRMI Included in our AI-picked strategies Review strategies 6.18 ▲ +0.09 (+1.48%) Closed · 15:59:59 · USD 6.13 ▼ -0.05 (-0.81%) After Hours · 21:17:38 1D 1W 1M 6M 1Y 5Y Max Created with Highcharts 11.4.8 14:00 15:00 16:00 17:00 18:00 19:00 5.96 6.1 6.2 Analyze FRMI

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Is FRMI a bargain right now? The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for FRMI plus thousands of other stocks and find your next hidden gem with massive upside. See Undervalued Stocks

Risks

  • Fermi Inc. faces challenges with weak financial health, as indicated by a substantial net loss and revenue shortfalls in the first quarter of 2026.
  • The stock has declined 81% over the past year, trading at $6.18, significantly below its 52-week high of $36.99, indicating potential market volatility and investor concern.
  • Ongoing governance changes, including a former CEO's advocacy for a board change and disputes over termination claims, may impact company stability and strategic direction.

More from Insider Trading

Rackspace Technology Executive Offloads Shares to Cover Tax Obligations Amid Stock Surge Jun 4, 2026 Veracyte Executive Sells Nearly $700K in Shares Amid Product Rollouts and Analyst Upgrades Jun 4, 2026 Veracyte Executive Traces Share Disposition Amid Clinical Milestones and Valuation Scrutiny Jun 4, 2026 Veracyte CFO Executes $177K Stock Sale Amid Clinical Trial Updates and Analyst Revisions Jun 4, 2026 Veracyte Executive Divests Stake Amid Diagnostic Expansion and Valuation Debate Jun 4, 2026